| bevacizumab治疗乳腺癌的基础和临床研究 |
| |
| 引用本文： | 任文晓,江泽飞,宋三泰.bevacizumab治疗乳腺癌的基础和临床研究[J].国外医学(肿瘤学分册),2006(8). |
| |
| 作者姓名： | 任文晓 江泽飞 宋三泰 |
| |
| 作者单位： | 军事医学科学院附属医院肿瘤中心，军事医学科学院附属医院肿瘤中心，军事医学科学院附属医院肿瘤中心 |
| |
| 摘 要： | 分子靶向药物bevacizumab是针对血管内皮生长因子(VEGF)的重组人源化单克隆抗体,在多种恶性肿瘤的治疗中显示了临床效果。现就bevacizumab的作用机制及其在乳腺癌治疗中的临床研究进展作一综述。
|
| 关 键 词： | 乳腺肿瘤 血管内皮生长因子类 抗体 单克隆 |
Base and clinical advances of bevacizumab for breast cancer |
| |
| REN Wen-xiao.Cancer Center of Hos- pital Affiliated Academy Military Medical Science,Beijing ,China.Base and clinical advances of bevacizumab for breast cancer[J].Foreign Medical Sciences (Cancer Section),2006(8). |
| |
| Authors: | REN Wen-xiaoCancer Center of Hos- pital Affiliated Academy Military Medical Science Beijing China |
| |
| Affiliation: | REN Wen-xiao.Cancer Center of Hos- pital Affiliated Academy Military Medical Science,Beijing 100071,China |
| |
| Abstract: | The targeted drug bevacizumab is an anti-VEGF monoclonal antibody,it has clinical effect on many malignant tumors.This article will review on the mechanism and clinical advances of bev- acizumab for breast cancer. |
| |
| Keywords: | Breast neoplasms Vascular endothelial growth factor Antibodies monoelonal |
| 本文献已被 CNKI 等数据库收录！ |
